Phase 4Recruiting
Glycemic Variability of Combination Therapies in T2DM
A Multicenter Study to Evaluate Efficacy and Safety
- Sponsor
- JW Pharmaceutical (Industry)
- Enrollment
- 178 planned
- Conditions
- Type 2 Diabetes Mellitus (T2DM)
- Interventions
- Empagliflozin/Metformin; Anagliptin; Metformin; Empagliflozin/Linagliptin
- Ages
- adults, older adults
- Registry
- NCT07442006
Full record on ClinicalTrials.gov
From the registry
Glycemic Variability of Combination Therapies in T2DM
Primary outcomes
- Mean change in Mean Amplitude of Glycemic Excursion (MAGE) from baseline to week 12
History
Primary completion expected
Registered
Started